



Form PTO-1449

Attorney's Docket No.
39754-0674AApplication Serial No.
10/000,439

INFORMATION DISCLOSURE STATEMENT

Applicant(s) ANDREW SAXON, et al.

(use several sheets if necessary)

Filing Date:
October 24, 2001Group Art Unit:
1644

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
PNK ↓	1.	10-07-2004	US 2004/0198961A1	An et al.	530	391.1	
	2.	03-13-2003	US 2003/0049237A1	Bannon et al.	424	93.21	
	3.	12-20-2001	US 20010053770A1	Thomas et al.	514	44	
	4.	04-24-2003	US 2003/0077282 A1	Bigler et al.	424	144.1	
	5.	03-28-2000	6,043,345	Saxon et al.	530	387.1	
	6.	10-08-1996	5,563,250	Hylarides et al.	536	4.1	
	7.	10-27-1998	5,827,516	Urban et al.	424	93.2	
	8.	09-22-1998	5,811,265	Quertermous et al.	435	68.3	
	9.	07-25-2000	6,093,699	Sehon et al.	514	44	
	10.	10-12-1999	5,965,605	Cheng et al.	514	454	
	11.	05-21-1991	5,017, 693	Hylarides et al.	530	390	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation	
							YES	NO
PNK ↓	12.	12-27-2002	WO 02/102320 A2	PCT	A61K			
	13.	12-27-2002	WO 2002/102320 A3	PCT	C12N	45/00		
	14.	05-02-1996	WO 96/12740	PCT	C07K	46/100		
	15.	10-05-1995	WO 95/26365	PCT	C07K	49/00		

OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
PNK ↓	16.	Abdelilah, S. G. et al., "Molecular characterization of the low-affinity IgE receptor FcεRII/CD23 expressed by human eosinophils, International Immunology, Vol. 10, No. 4, pp 395-404, April 1998.
	17.	Abramson, M. J., et al., "Allergen immunotherapy for asthma", The Cochrane Library, Issue 1, pp. 1-32, 1999.
	18.	Akdis, C. A., et al., "Epitope-specific T Cell Tolerance to Phospholipase A2 in Bee Venom Immunotherapy and Recovery by IL-2 and IL-15 In Vitro", Journal of Clinical Investigation, Vol. 98, No. 7, pp. 1676-1683, October 1996.
	19.	Brazis, P., et al., "Stem cell factor enhances IgE-mediated histamine and TNF-α release from dispersed canine cutaneous mast cells", Veterinary Immunology and Immunopathology, Vol. 75, pp. 97-108, 2000.
	20.	Campbell, K. A., et al., "Co-crosslinking FcεRII/CD23 and B cell surface immunoglobulin modulates B cell activation", Eur. J. Immunol., Vol. 22, pp. 2107-2112, 1992.
	21.	Castells, M., M.D., Ph.D., "Mast Cells: Molecular And Cell Biology", The Internet Journal of Asthma, Allergy And Immunology, Vol. 11N1, pp. 1-17, 1999.
	22.	Daëron, Marc, "Fcγ-RIIB as potential therapeutic targets for allergic diseases", NAID Symposium 1221, Rethinking Immunotherapy for the Twenty First Century: Bench to Bedside, presented at the Annual Meeting of the American Academy of Allergy, Allergy Asthma & Immunology, March 16-21, 2001 New Orleans, LA.
	23.	Guo, C. B., et al., "Identification of IgE-bearing Cells in the Late-phase Response to Antigen in the Lung as Basophils", American J. Respir. Cell Mol. Biol., Vol. 10, No. 4, pp 384-90, 1994.
	24.	Henz, B. M., et al., "Urticaria - New Developments and Perspectives", Hautarzt, Vol. 51, pp. 302-308, 2000.


EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2113550 v1



Form PTO-1449		Attorney's Docket No. 39754-0674A	Application Serial No. 10/000,439
INFORMATION DISCLOSURE STATEMENT		Applicant(s) ANDREW SAXON, et al.	
(use several sheets if necessary)		Filing Date: October 24, 2001	Group Art Unit: 1644
Pnt	25.	Hulett, M. D., et al., "Fine Structure Analysis of Interaction of FcεRI with IgE", The Journal of Biological Chemistry, Vol. 274, No. 19, pp. 13345-13352, 1999.	
	26.	Kawabori, S., et al., "Existence of c-kit Receptor-Positive, Tryptase-Negative, IgE-Negative Cells in Human Allergic Nasal Mucosa: A Candidate for Mast Cell Progenitor", International Archives of Allergy and Immunology, Vol. 112, pp. 36-43, 1997.	
	27.	Kepley, C., et al., "Purification of human basophils by density and size alone", Journal of Immunological Methods, Vol. 175, pp. 1-9, 1994.	
	28.	Kepley, C., et al., "Identification and Partial Characterization of a Unique Marker for Human Basophils", The Journal of Immunology, Vol. 154, pp. 6548-6555, 1995.	
	29.	Kepley, C., et al., "The identification and characterization of umbilical cord blood-derived human basophils", Journal of Leukocyte Biology, Vol. 64, pp. 474-483, 1998.	
	30.	Kepley et al., "FcεRI-FcγRII, Coaggregation inhibits IL-16 production fro human langerhans-like dendric cells", Clinical Immunology, Vol. 108, No. 89-94, 2003.	
	31.	Liénard, H., et al., "Signal Regulatory Proteins Negatively Regulate Immunoreceptor-dependent Cell Activation", The Journal of Biological Chemistry, Vol. 274, No. 45, Issue of November 5, pp. 32493-32499, 1999.	
	32.	Lin, S., et al., "Giving Inhibitory Receptors a Boost", Science's Compass, Vol. 291, pp. 445-446, January 19, 2001.	
	33.	Machiels, J. J., et al., "Significant Reduction of Nonspecific Bronchial Reactivity in Patients with <i>Dermatophagoides pteronyssinus</i> -sensitive Allergic Asthma under Therapy with Allergen-Antibody Complexes", Am. Rev. Respir. Dis., Vol. 147, pp. 1407-1412, 1993.	
	34.	Machiels, J. J., et al., "Complexes of grass pollen allergens and specific antibodies reduce allergic symptoms and inhibit the seasonal increase of IgE antibody", Clinical and Experimental Allergy, Vol. 20, pp. 653-660, 1990.	
	35.	Machiels, J. J., et al., "Allergen-antibody complexes can efficiently prevent seasonal rhinitis and asthma in grass pollen hypersensitive patients", Allergy, Vol. 46, pp. 335-348, 1991.	
	36.	Machiels, J. J., et al., "Allergic Bronchial Asthma Due to <i>Dermatophagoides pteronyssinus</i> Hypersensitivity Can Be Efficiently Treated by Inoculation of Allergen-Antibody Complexes", The American Society for Clinical Investigation, Inc., Vol. 85, pp. 1024-1035, 1990.	
	37.	Milgrom, H., et al., "Treatment of Allergic Asthma with Monoclonal Anti-IgE Antibody", The New England Journal of Medicine, Vol. 341, No. 26, pp. 1966-1973, December 23, 1999.	
	38.	Minerd, J., "Experimental Therapy Stops Allergic Reactions in Mice", <i>NIAID News</i> , pp 1-3, May 2002.	
	39.	Nakagawa, T., et al., "Immunotherapy of Allergic Diseases", Int. Arch. Allergy Immunol., Vol. 102, pp. 117-120, 1993.	
	40.	Ngo, J. T. et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox" from "The Protein Folding Problem and Tertiary Structure Prediction", pp 433 and 492-495, Kenneth J. Merz and Scott M. Le Grand, Editors, Birkhauser, Boston, MA, 1994	
	41.	Osborne, M. A., et al., "The Inositol 5'-Phosphatase SHIP Binds to Immunoreceptor Signaling Motifs and Responds to High Affinity IgE Receptor Aggregation", The Journal of Biological Chemistry, Vol. 271, No. 46, pp. 29271-29278, 1996.	
	42.	Phillips, Nancy E., et al., "Cross-Linking Of B Lymphocyte Fcγ Receptors And Membrane Immunoglobulin Inhibits Anti-Immunoglobulin-Induced Blastogenesis", The Journal Of Immunology, Vol. 132, No. 2, pp 627-632, February 1984.	
	43.	Pivnyuk, V. I., et al., "Human Low-Affinity IgE Receptor; cDNA from Cell Line 1B and Its Expression in Peripheral Blood Cells", Molecular Biology, Vol. 28, No. 4, Part 2, pp. 549-552, 1994.	
	44.	Schwartz, L. B., M.D., Ph.D., et al., "Development of markers for human basophils and mast cells", J. Allergy Clin. Immunol., Vol. 94, No. 6, Part 2, pp. 1231-1240, 1994.	
↓	45.	Shields, R. et al., "High Resolution Mapping of the Binding on Human IgG1 for FcγRI, FcγRII, FcγRIII and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR", The Journal of Biological Chemistry, Vol. 276, No. 9, pp 6591-6604, 2001.	


EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2113550 v1



Form PTO-1449		Attorney's Docket No. 39754-0674A	Application Serial No. 10/000,439
INFORMATION DISCLOSURE STATEMENT		Applicant(s) ANDREW SAXON, et al.	
(use several sheets if necessary)		Filing Date: October 24, 2001	Group Art Unit: 1644
46.	Suter, U., et al., "Expression of Human Lymphocyte IgE Receptor (Fc ϵ R/CD23)", The Journal of Immunology, Vol. 143, No. 9, pp. 3087-3092, November 1, 1989.		
47.	Wang, M., et al., "Early IL-4 Production Driving Th2 Differentiation in a Human <i>in Vivo</i> Allergic Model Is Mast Cell Derived", Clinical Immunology, Vol. 90, No. 1, pp. 47-54, 1999.		
48.	Yabuuchi, S., et al., "Anti-CD23 monoclonal antibody inhibits germline C ϵ transcription in B cells", International Immunopharmacology, Vol. 2, pp. 453-461, 2002.		
49.	Yamashita, T., et al., "Expression Cloning of Complementary DNA Encoding Three Distinct Isoforms of Guinea Pig Fc Receptor for IgG1 and IgG2 γ ", The Journal of Immunology, Vol. 151, No. 4, pp. 2014-2023, August 15, 1993.		
50.	Yamashita, Y., et al., "Inhibitory and Stimulatory Functions of Paired Ig-Like Receptor (PIR) Family in RBL-2H3 Cells ¹ ", The American Association of Immunologists, Vol. 161, pp. 4042-4047, 1998.		
51.	van Rosenberg, S. M. W., et al., "A Structure-Function Study of Ligand Recognition by CD22 β ", The Journal of Biological Chemistry, Vol. 276, No. 16, pp. 12967-12973, 2001.		

EXAMINER:	DATE CONSIDERED: 6/6/05
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant. *If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	
SV 2113550 v1	